| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
132.26(B) |
| Last
Volume: |
14,116,634 |
Avg
Vol: |
12,004,727 |
| 52
Week Range: |
$39.66 - $59.82 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 243 |
| Guru Rank Value : 6.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,071 |
13,571 |
| Total Buy Value |
$0 |
$0 |
$249,609 |
$672,994 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
320,286 |
| Total Sell Value |
$0 |
$0 |
$0 |
$23,276,473 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
5 |
| End Date |
2024-08-25 |
2024-05-24 |
2023-11-24 |
2022-11-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Holzer Phil M |
SVP and Controller |
• – – |
2024-11-04 |
4 |
S |
$55.62 |
$38,931 |
D/D |
(700) |
11,760 |
|
-6% |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2024-11-01 |
4 |
B |
$54.68 |
$100,055 |
D/D |
1,830 |
62,109 |
2.74 |
8% |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-11-01 |
4 |
D |
$54.32 |
$80,828 |
D/D |
(1,488) |
102,626 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-11-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(55) |
104,114 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,964 |
104,169 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-10-02 |
4 |
D |
$53.76 |
$88,596 |
D/D |
(1,648) |
5,019 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-10-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,558 |
6,667 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-08-01 |
4 |
D |
$48.17 |
$18,497 |
D/D |
(384) |
2,109 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,061 |
2,493 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2024-04-01 |
4 |
D |
$52.99 |
$63,376 |
D/D |
(1,196) |
5,336 |
|
- |
|
| Shanahan Karin |
EVP, Glob. Prod. Dev. & Supply |
• – – |
2024-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,306 |
6,532 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$896,141 |
D/D |
(16,660) |
347,385 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,153) |
359,080 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,784 |
371,312 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$37,438 |
D/D |
(696) |
1,432 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(839) |
1,926 |
|
- |
|
| Gallman Cari |
EVP, Corporate Affairs |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,761 |
2,655 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-03-10 |
4 |
D |
$53.79 |
$1,043,903 |
D/D |
(19,407) |
101,205 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,698) |
115,180 |
|
- |
|
| Boerner Christopher S. |
Chief Executive Officer |
• • – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,638 |
129,769 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$996,298 |
D/D |
(18,522) |
194,968 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,448) |
208,313 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
64,326 |
225,111 |
|
- |
|
| Hoch Lynelle |
President, Cell Therapy Org. |
• – – |
2024-03-10 |
4 |
D |
$53.79 |
$70,357 |
D/D |
(1,308) |
1,726 |
|
- |
|
| Hoch Lynelle |
President, Cell Therapy Org. |
• – – |
2024-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,317) |
2,643 |
|
- |
|
940 Records found
|
|
Page 1 of 38 |
|
|
0.09 (0.15%) 
